Doctors often prescribe cholesterol-lowering drugs to help people stay healthy as they get older. These medicines are mainly ...

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert ...

Having high blood cholesterol levels (hypercholesterolemia) is a risk factor for heart diseases like heart attacks and strokes because it can lead to plaque buildup, which can restrict blood flow. For ...

Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...

"Clinically, there's heterogeneity among secondary-prevention patients," Dr Marc S Sabatine (Brigham and Women's Hospital, Boston, MA), who presented the former report on the three risk markers, told ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...

MK-0616, an experimental oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, met its primary endpoint and substantially reduced levels of low-density lipoprotein (LDL) cholesterol in ...

PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...